JP5415279B2 - アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 - Google Patents

アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 Download PDF

Info

Publication number
JP5415279B2
JP5415279B2 JP2009542880A JP2009542880A JP5415279B2 JP 5415279 B2 JP5415279 B2 JP 5415279B2 JP 2009542880 A JP2009542880 A JP 2009542880A JP 2009542880 A JP2009542880 A JP 2009542880A JP 5415279 B2 JP5415279 B2 JP 5415279B2
Authority
JP
Japan
Prior art keywords
polypeptide
composition
activin
actriia
actrii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009542880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513506A5 (https=
JP2010513506A (ja
Inventor
マシュー エル． シャーマン，
Original Assignee
アクセルロン ファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ， インコーポレイテッド filed Critical アクセルロン ファーマ， インコーポレイテッド
Publication of JP2010513506A publication Critical patent/JP2010513506A/ja
Publication of JP2010513506A5 publication Critical patent/JP2010513506A5/ja
Application granted granted Critical
Publication of JP5415279B2 publication Critical patent/JP5415279B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2009542880A 2006-12-18 2007-12-18 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 Active JP5415279B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87568206P 2006-12-18 2006-12-18
US60/875,682 2006-12-18
PCT/US2007/025868 WO2008076437A2 (en) 2006-12-18 2007-12-18 Activin-actrii antagonists and uses for increasing red blood cell levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013055102A Division JP5865281B2 (ja) 2006-12-18 2013-03-18 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用

Publications (3)

Publication Number Publication Date
JP2010513506A JP2010513506A (ja) 2010-04-30
JP2010513506A5 JP2010513506A5 (https=) 2012-02-09
JP5415279B2 true JP5415279B2 (ja) 2014-02-12

Family

ID=39183159

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2009542880A Active JP5415279B2 (ja) 2006-12-18 2007-12-18 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2013055102A Active JP5865281B2 (ja) 2006-12-18 2013-03-18 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2013243668A Pending JP2014040483A (ja) 2006-12-18 2013-11-26 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2015211115A Pending JP2016020391A (ja) 2006-12-18 2015-10-27 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2017018409A Pending JP2017075187A (ja) 2006-12-18 2017-02-03 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2017119494A Withdrawn JP2017155064A (ja) 2006-12-18 2017-06-19 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2019044553A Withdrawn JP2019089850A (ja) 2006-12-18 2019-03-12 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2021032007A Pending JP2021080290A (ja) 2006-12-18 2021-03-01 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2013055102A Active JP5865281B2 (ja) 2006-12-18 2013-03-18 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2013243668A Pending JP2014040483A (ja) 2006-12-18 2013-11-26 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2015211115A Pending JP2016020391A (ja) 2006-12-18 2015-10-27 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2017018409A Pending JP2017075187A (ja) 2006-12-18 2017-02-03 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2017119494A Withdrawn JP2017155064A (ja) 2006-12-18 2017-06-19 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2019044553A Withdrawn JP2019089850A (ja) 2006-12-18 2019-03-12 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP2021032007A Pending JP2021080290A (ja) 2006-12-18 2021-03-01 アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用

Country Status (30)

Country Link
US (7) US7988973B2 (https=)
EP (6) EP2468291B1 (https=)
JP (8) JP5415279B2 (https=)
KR (6) KR20210027508A (https=)
CN (4) CN104524548A (https=)
AU (1) AU2007334333B2 (https=)
BR (1) BRPI0720476B1 (https=)
CA (1) CA2672758C (https=)
CO (1) CO6230995A2 (https=)
CR (1) CR10889A (https=)
DK (2) DK2124999T3 (https=)
EA (3) EA018037B1 (https=)
EC (1) ECSP099514A (https=)
ES (1) ES2396734T3 (https=)
HK (2) HK1209624A1 (https=)
HR (1) HRP20121035T1 (https=)
IL (5) IL199451A (https=)
ME (1) ME02335B (https=)
MX (2) MX2009006651A (https=)
MY (3) MY188973A (https=)
NZ (4) NZ577847A (https=)
PH (1) PH12013500310B1 (https=)
PL (2) PL2468290T3 (https=)
PT (1) PT2124999E (https=)
RS (1) RS52537B (https=)
SG (1) SG10201702157QA (https=)
SI (1) SI2124999T1 (https=)
UA (2) UA101309C2 (https=)
WO (1) WO2008076437A2 (https=)
ZA (2) ZA200904454B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526626A (ja) * 2008-06-26 2011-10-13 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46351E1 (en) 2001-05-10 2017-03-28 Battelle Energy Alliance, Llc Antibody profiling sensitivity through increased reporter antibody layering
US6989276B2 (en) 2001-05-10 2006-01-24 Battelle Energy Alliance, Llc Rapid classification of biological components
JP2008507288A (ja) * 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
MX2009008222A (es) * 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
US20080286881A1 (en) * 2007-05-14 2008-11-20 Apel William A Compositions and methods for combining report antibodies
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
CN102131822A (zh) * 2008-06-26 2011-07-20 阿塞勒隆制药公司 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
AU2015202035B2 (en) * 2008-08-14 2017-03-23 Acceleron Pharma Inc. Use of GDF traps to increase red blood cell levels
WO2010045518A1 (en) * 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
JP5611222B2 (ja) 2008-11-26 2014-10-22 アムジエン・インコーポレーテツド アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
KR20180026795A (ko) * 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
AU2010282361B2 (en) * 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
EP3202459B1 (en) * 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
US9410965B2 (en) * 2009-09-17 2016-08-09 Battelle Energy Alliance, Llc Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual
US8969009B2 (en) * 2009-09-17 2015-03-03 Vicki S. Thompson Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual
AU2010315245B2 (en) * 2009-11-03 2016-11-03 Acceleron Pharma Inc. Methods for treating fatty liver disease
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012027065A2 (en) * 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
US12612370B2 (en) 2011-03-02 2026-04-28 Thermolife International, Llc Amino acid compositions
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
GB201206559D0 (en) * 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
WO2014030683A1 (ja) * 2012-08-21 2014-02-27 国立大学法人九州大学 貧血患者の貧血の要因を検出するためのバイオマーカー
HK1214504A1 (zh) 2012-10-24 2016-07-29 细胞基因公司 用於治療貧血的方法
CN104968801B (zh) * 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
US10195249B2 (en) * 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP2017509647A (ja) * 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
EA202090632A1 (ru) 2014-06-04 2020-07-31 Акселерон Фарма Инк. Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
JP2018501307A (ja) * 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CN107428818A (zh) * 2015-01-29 2017-12-01 密西根州立大学校董会 隐藏多肽及其用途
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
EP3274457A4 (en) 2015-03-26 2018-08-08 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
MA41920B1 (fr) 2015-04-06 2021-05-31 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
US20180125928A1 (en) * 2015-05-13 2018-05-10 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
CN108350057A (zh) * 2015-05-20 2018-07-31 细胞基因公司 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
KR102605758B1 (ko) * 2015-07-06 2023-11-23 미츠비시 가스 가가쿠 가부시키가이샤 수지 조성물, 프리프레그, 레진 시트, 적층판, 및 프린트 배선판
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3380121B1 (en) * 2015-11-23 2023-12-20 Acceleron Pharma Inc. Actrii antagonist for use in treating eye disorders
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
DK3496739T3 (da) 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
MA45811A (fr) 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.
JP6944768B2 (ja) 2016-08-29 2021-10-06 エア・ウォーター株式会社 ペリクルの製造方法
CN110036025B (zh) 2016-10-05 2024-03-22 阿塞勒隆制药公司 变体ActRIIB蛋白及其用途
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
NZ754161A (en) 2016-11-10 2025-11-28 Keros Therapeutics Inc Activin receptor type iia variants and methods of use thereof
LT3600415T (lt) 2017-03-24 2025-12-29 Novartis Ag Antikūnas prieš ii tipo aktivino receptorių, skirtas naudoti širdies nepakankamumo gydymui
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
KR20220107252A (ko) 2019-11-29 2022-08-02 키맵 리미티드 생리학적 철분 과다에 대한 치료
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
WO2021189019A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
AU2022220004A1 (en) 2021-02-11 2023-08-17 Thermolife International, Llc A method of administering nitric oxide gas
CA3226249A1 (en) * 2021-08-16 2023-02-23 Thermolife International, Llc Iron supplement compositions and methods of use thereof
US11945856B2 (en) 2022-01-28 2024-04-02 35Pharma Inc. Activin receptor type IIB variants and uses thereof
AU2024231427A1 (en) * 2023-03-09 2025-09-04 Merck Sharp & Dohme Llc Formulations comprising actriia polypeptide variants
US20260092096A1 (en) 2024-05-14 2026-04-02 35Pharma Inc. Activin receptor type iib variants and uses thereof
WO2025250605A1 (en) * 2024-05-31 2025-12-04 Eli Lilly And Company Acvr2a and acvr2b rna interference agents

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US71927A (en) * 1867-12-10 Improvement in apparatus fob turning on gas
JPH0637520B2 (ja) 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4973577A (en) 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
EP0548276A4 (en) * 1990-09-13 1993-12-29 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
EP0542971A1 (en) 1991-05-10 1993-05-26 The Salk Institute For Biological Studies CLONING AND RECOMBINANT PRODUCTION OF RECEPTOR(S) OF THE ACTIVIN/TGF-$g(b) SUPERFAMILY
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
JPH09503673A (ja) 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US6132988A (en) 1995-10-27 2000-10-17 Takeda Chemical Industries, Ltd. DNA encoding a neuronal cell-specific receptor protein
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
MXPA01007366A (es) 1999-01-21 2002-06-04 Metamorphix Inc Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
AU777783B2 (en) 1999-04-19 2004-10-28 Kyowa Hakko Kogyo Co. Ltd. Proliferation inhibitor for androgen-independent tumor
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
IL150198A0 (en) * 1999-12-15 2002-12-01 Res Dev Foundation Betaglycan as an inhibin receptor and uses thereof
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
AU2002236558A1 (en) 2000-12-01 2002-06-11 Regents Of The University Of California Method and composition for modulating bone growth
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
EP1572909A4 (en) 2002-02-21 2007-06-06 Wyeth Corp PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
JP2004121008A (ja) * 2002-09-30 2004-04-22 Toray Ind Inc ネコアクチビンａおよびそのサブユニット並びにその製造法
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US20040197828A1 (en) 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
WO2005028517A2 (en) 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
RU2322261C2 (ru) 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
WO2005009460A2 (en) * 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2005094871A2 (en) 2004-03-26 2005-10-13 Acceleron Pharma Inc. Bmp-3 propeptides and related methods
CA2561809A1 (en) 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
EP1771557B1 (en) 2004-06-24 2014-12-31 Acceleron Pharma Inc. GDF3 Propeptides and Related Methods
JP2008507288A (ja) * 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
WO2006039400A2 (en) 2004-09-29 2006-04-13 Mount Sinai School Of Medicine Of New York University Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
WO2006088972A2 (en) 2005-02-16 2006-08-24 The General Hospital Corporation Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism
EP1884235A1 (en) * 2005-04-26 2008-02-06 Ajinomoto Co., Inc. Myeloerythroid progenitor differentiation inducer
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
ES2649983T3 (es) * 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
WO2007067616A2 (en) 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
WO2007084977A2 (en) 2006-01-20 2007-07-26 Beckman Coulter, Inc. Low hemoglobin concentration cell percentage and method of use in detection of iron deficiency
US20080075692A1 (en) 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
ES2382993T3 (es) 2006-07-21 2012-06-15 Lyne Laboratories, Inc. Composición líquida de acetato de calcio
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
MX2009012934A (es) 2007-06-01 2009-12-15 Wyeth Corp Metodos y composiciones para modular la actividad de bmp-10.
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
JP2011523357A (ja) 2008-05-06 2011-08-11 ジョスリン ダイアビーティス センター インコーポレイテッド 褐色脂肪細胞分化を誘導するための方法および組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526626A (ja) * 2008-06-26 2011-10-13 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
JP2014088438A (ja) * 2008-06-26 2014-05-15 Acceleron Pharma Inc アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用

Also Published As

Publication number Publication date
PT2124999E (pt) 2013-01-22
US20210355191A1 (en) 2021-11-18
AU2007334333A1 (en) 2008-06-26
NZ617196A (en) 2015-06-26
IL199451A (en) 2015-08-31
SI2124999T1 (sl) 2013-02-28
CN105582521A (zh) 2016-05-18
KR20090096517A (ko) 2009-09-10
JP5865281B2 (ja) 2016-02-17
US20120052067A1 (en) 2012-03-01
HK1137368A1 (en) 2010-07-30
KR101688228B1 (ko) 2016-12-21
MX373050B (es) 2020-05-21
US20200031903A1 (en) 2020-01-30
PL2124999T3 (pl) 2013-03-29
EA200970603A1 (ru) 2009-12-30
EP2124999A2 (en) 2009-12-02
EP3320911A2 (en) 2018-05-16
KR20150064239A (ko) 2015-06-10
CR10889A (es) 2009-09-01
MY170509A (en) 2019-08-08
CN101687015A (zh) 2010-03-31
EA035911B1 (ru) 2020-08-31
KR101831534B1 (ko) 2018-02-22
AU2007334333A2 (en) 2011-05-12
EP2124999B1 (en) 2012-10-03
EA202091230A3 (ru) 2021-01-29
UA116871C2 (uk) 2018-05-25
KR20160013269A (ko) 2016-02-03
RS52537B (sr) 2013-04-30
WO2008076437A2 (en) 2008-06-26
US8007809B2 (en) 2011-08-30
DK2468290T3 (en) 2015-06-01
KR102223231B1 (ko) 2021-03-08
JP2014040483A (ja) 2014-03-06
CN105797135A (zh) 2016-07-27
HK1209624A1 (en) 2016-04-08
IL256247B (en) 2021-07-29
BRPI0720476A2 (pt) 2014-01-14
IL240524A (en) 2017-06-29
JP2016020391A (ja) 2016-02-04
PH12013500310B1 (en) 2018-09-21
CO6230995A2 (es) 2010-12-20
CA2672758A1 (en) 2008-06-26
HK1254840A1 (en) 2019-07-26
IL284693A (en) 2021-08-31
IL240523A (en) 2017-12-31
US20090163417A1 (en) 2009-06-25
ES2396734T3 (es) 2013-02-25
WO2008076437A9 (en) 2008-11-13
US20220204588A1 (en) 2022-06-30
DK2124999T3 (da) 2013-01-14
JP2013127002A (ja) 2013-06-27
MY162136A (en) 2017-05-31
WO2008076437A3 (en) 2008-09-18
JP2010513506A (ja) 2010-04-30
US7988973B2 (en) 2011-08-02
NZ577847A (en) 2012-06-29
CN101687015B (zh) 2016-08-03
HRP20121035T1 (hr) 2013-01-31
BRPI0720476B1 (pt) 2022-05-31
SG10201702157QA (en) 2017-04-27
EP2468290A1 (en) 2012-06-27
EP3320911B1 (en) 2021-12-01
EP2468290B1 (en) 2015-04-01
IL240523A0 (en) 2015-10-29
JP2021080290A (ja) 2021-05-27
EP2468291B1 (en) 2017-11-22
EP3320911A3 (en) 2018-06-27
ECSP099514A (es) 2009-08-28
US20100204092A1 (en) 2010-08-12
EA201201199A1 (ru) 2013-10-30
EP2446896A1 (en) 2012-05-02
US20090047281A1 (en) 2009-02-19
PH12013500310A1 (en) 2013-04-01
IL256247A (en) 2018-02-28
ZA201202027B (en) 2013-02-27
CN104524548A (zh) 2015-04-22
NZ707292A (en) 2017-06-30
EA202091230A2 (ru) 2020-09-30
NZ720955A (en) 2019-07-26
KR20210027508A (ko) 2021-03-10
MY188973A (en) 2022-01-17
EP2468291A1 (en) 2012-06-27
JP2019089850A (ja) 2019-06-13
MX2009006651A (es) 2009-08-26
ME02335B (me) 2013-04-30
EP4026553A1 (en) 2022-07-13
EA018037B1 (ru) 2013-05-30
PL2468290T3 (pl) 2015-08-31
JP2017155064A (ja) 2017-09-07
IL240524A0 (en) 2015-10-29
ZA200904454B (en) 2014-03-26
CA2672758C (en) 2019-07-30
UA101309C2 (ru) 2013-03-25
AU2007334333B2 (en) 2013-05-30
KR20180019768A (ko) 2018-02-26
KR101803620B1 (ko) 2017-11-30
KR20200030124A (ko) 2020-03-19
JP2017075187A (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
JP5415279B2 (ja) アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
JP5773868B2 (ja) アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
AU2020267232A1 (en) Activin-ActRII antagonists and uses for increasing red blood cell levels
HK1172548A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
HK1172547A1 (en) Activin-actrii antagonists for use in treating anemia
HK1172547B (en) Activin-actrii antagonists for use in treating anemia
HK1170177A (en) Activin-actrii antagonists for use in increasing red blood cells, increasing reticulocyte levels, or promoting erythropoiesis
HK1172548B (en) Activin-actrii antagonists and uses for increasing red blood cell levels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131113

R150 Certificate of patent or registration of utility model

Ref document number: 5415279

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250